Full-Time

Specialist System Administrator-Observability

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Mid, Senior

Hyderabad, Telangana, India

This position requires you to be onsite and participate in 24/5 and weekend on call in rotation fashion and may require you to work a later shift.

Category
System Administration
IT & Security
Required Skills
PowerShell
Kubernetes
Python
React.js
TypeScript
Ansible
Linux/Unix
Requirements
  • Master’s degree and 4 to 6 years of IT related field experience OR
  • Bachelor’s degree and 6 to 8 years of IT related field experience OR
  • Diploma and 10 to 12 years of IT related field experience
  • Advanced knowledge of monitoring and notification technologies, observability concepts using Dynatrace and Pagerduty
  • Experience with Infrastructure and Application monitoring, Windows, Linux, open telemetry and integrations
  • Experience with TypeScript, React, Ansible and Python scripting
  • Good understanding of networking, storage integration, and similar infrastructure services.
  • Change management expertise
  • Hands-on expertise in scripting and automation tools
  • Knowledge of containers and K8 environment
Responsibilities
  • Lead a high-performing team managing monitoring and observability services.
  • Develop and maintain the Dynatrace observability environment
  • Contribute to infrastructure design and architecture planning
  • Implement automation using PowerShell, Python, or Ansible
  • Monitor systems and proactively address performance bottlenecks
  • Collaborate with multi-functional teams on infrastructure needs
  • Document system configurations and operational procedures.
Desired Qualifications
  • Experience with cloud services (AWS, Azure, GCP)
  • Experience with ITIL processes and frameworks
  • Experience with CI/CD and DevOps practices
  • Understanding of configuration management and automation tools (Ansible and Terraform)

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.